G. Allan, J. Davis, M. Dickins, I. Gardner, T. Jenkins, H. Jones, R. Webster and H. Westgate, “Pre-Clinical Pharmacokinetics of UK-453,061, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), and Use of in Silico Physiologically Based Prediction Tools to Predict the Oral Pharmacokinetics of UK-453,061 in Man,” Xenobiotica, Vol. 38, No. 6, 2008, pp. 620-640. doi:10.1080/00498250802069088

has been cited by the following article:

• TITLE: Identification of HCV Inhibitors from a Cell-Based Sub-Genomic Replicon Screen

  AUTHORS: David C. Pryde, Thien-Duc Tran, Mark Gardner, Chris Pickford, Stephen M. Shaw, Mike Westby, Tanya Parkinson, Caroline Smith-Burchnell, Rob Webster, Satish Dayal

  KEYWORDS: HCV; Replicon; Antiviral; Cell-Based Screen

  JOURNAL NAME: Open Journal of Medicinal Chemistry, Vol.3 No.1, March 29, 2013

  ABSTRACT: A high throughput screen of the Pfizer compound collection was carried out using a hepatitis C virus (HCV) genotype 1b subgenomic replicon cell line. Those confirmed hits that demonstrated broad spectrum activity without overt cytotoxicity were further evaluated, leading to the identification of a series of pyrrolopyridines with excellent antiviral activity in a fully infectious HCV cell-based assay and pharmacokinetic properties.